Serum Calreticulin Is a Negative Biomarker in Patients with Alzheimer’s Disease
Calreticulin is down-regulated in the cortical neurons of patients with Alzheimer’s disease (AD) and may be a potential biomarker for the diagnosis of AD. A total of 128 AD patients were randomly recruited from May 2012 to July 2013. The mRNA levels of calreticulin were measured from the serum of...
Main Authors: | Qiao Lin, Yunpeng Cao, Jie Gao |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2014-11-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | http://www.mdpi.com/1422-0067/15/12/21740 |
Similar Items
-
Protein Kinase A Detection in Human Urine Samples
by: Angela Ragone, et al.
Published: (2021-09-01) -
The protection of Rosuvastatin and Ramipril against the development of nitrate tolerance in the rat and mouse aorta./ La protection de la Rosuvastatine et du Ramipril vis-à-vis du développement de la tolérance à la nitroglycérine dans l'aorte de rats et de souris.
by: Otto, Anne
Published: (2006) -
Surface-exposed and soluble calreticulin: conflicting biomarkers for cancer prognosis
by: Oliver Kepp, et al.
Published: (2020-01-01) -
A novel autoantibody targeting calreticulin is associated with cancer in patients with idiopathic inflammatory myopathies
by: He Chen, et al.
Published: (2020-01-01) -
Lyme disease – principles of diagnosis and treatment
by: Sławomir A. Pancewicz
Published: (2014-06-01)